Comparison of Balanced Crystalloids and Normal Saline in Septic Patients
- Conditions
- SepsisAcute Kidney InjurySeptic ShockSepsis, Severe
- Interventions
- Drug: lactated Ringer's solutionDrug: 0.9% saline
- Registration Number
- NCT03685214
- Lead Sponsor
- ZhiYong Peng
- Brief Summary
In this prospective randomized controlled trial, investigators attempt to study the effects of acetated Ringer's solution on the prognosis and renal function of patients with sepsis in intensive care unit compared with normal saline, and provide evidence for current fluid resuscitation strategies for sepsis.
- Detailed Description
During the study period,either normal saline or acetated Ringer's solution will be assigned as resuscitation fluid to the septic patients meeting the inclusion criteria.It is anticipated that about 500 patients will be enrolled during the study period.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 500
- Patients diagnosed sepsis aged 18~75 and accepted therapy in ICU
- Need of Renal replacement treatment
- End-stage renal failure
- pregnant woman
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description Balanced Crystalloids lactated Ringer's solution We use acetated Ringer's solution for resuscitation fluid in ICU septic patients 0.9% saline 0.9% saline We use 0.9% saline for resuscitation fluid in ICU septic patients
- Primary Outcome Measures
Name Time Method Development of kidney injury as defined by the KDIGO criteria. 5 days after the admission Investigators will use the level of creatinine(μmol/L) and body weight adjusted urine(ml/h/kg) for severity assessment of kidney injury
Need of renal replacement treatment After the admission and before the discharge from ICU,average 15 days Investigators will assess patients' kidney function everyday
- Secondary Outcome Measures
Name Time Method ICU stay After the admission and before the discharge from ICU,average 15 days the time of patients' requirement for critical care
28 days mortality 28 days after the admission in ICU the short time mortality
Trial Locations
- Locations (1)
Zhongnan Hospital
🇨🇳Wuhan, Hubei, China